I’ve spent 30 years in medtech and biotech—from the bench to the production floor to the C-suite—bringing more than 25 products to market across FDA 510(k), CE/MDR, and TGA pathways. I’ve seen exceptional science fail, not because the innovation wasn’t strong, but because the operational, regulatory, and governance foundations weren’t in place to support commercialization. […]